UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1/CCL5 mediated M1 macrophage polarization in melanoma

Biomaterials, 2025-03, Vol.314, p.122815, Article 122815

2025

Volltextzugriff (PDF)

In vitro activities of the essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin, and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: a multicenter study in China, 2021

International journal of antimicrobial agents, 2024-09, p.107341, Article 107341

2024

Volltextzugriff (PDF)

Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective

Expert opinion on pharmacotherapy, 2021-02, Vol.22 (2), p.167-177

2021

Volltextzugriff (PDF)

Comparison of antimicrobial activities and resistance mechanisms of eravacycline and tigecycline against clinical Acinetobacter baumannii isolates in China

Frontiers in microbiology, 2024-09, Vol.15

2024

Volltextzugriff (PDF)

Efficacy and safety of eravacycline: A meta-analysis

Journal of global antimicrobial resistance., 2021-03, Vol.24, p.424-428

2021

Volltextzugriff (PDF)

An in silico study on reproposing eravacycline as an MMP inhibitor

Journal of applied pharmaceutical science, 2023-01

2023

Volltextzugriff (PDF)

Achromobacter Infections and Treatment Options

Antimicrobial agents and chemotherapy, 2020-10, Vol.64 (11)

2020

Volltextzugriff (PDF)

Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance

Annals of medicine (Helsinki), 2022-12, Vol.54 (1), p.1686-1700

2022

Volltextzugriff (PDF)

2018 FDA drug approvals

Nature reviews. Drug discovery, 2019-02, Vol.18 (2), p.85-89

Mullard, Asher

2019

Volltextzugriff (PDF)

In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015

Diagnostic microbiology and infectious disease, 2018-05, Vol.91 (1), p.55-62

2018

Volltextzugriff (PDF)

Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline

Antimicrobial agents and chemotherapy, 2018-11, Vol.62 (11)

2018

Volltextzugriff (PDF)

IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections

Clinical infectious diseases, 2019-08, Vol.69 (6), p.921-929

2019

Volltextzugriff (PDF)

Eravacycline -Synergistic activity with other antimicrobials in carbapenem resistant isolates of Escherichia coli and Acinetobacter baumannii

Diagnostic microbiology and infectious disease, 2023-11, Vol.107 (3), p.116006-116006, Article 116006

2023

Volltextzugriff (PDF)

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

Antimicrobial agents and chemotherapy, 2019-06, Vol.63 (6)

2019

Volltextzugriff (PDF)

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017

Antimicrobial agents and chemotherapy, 2020-02, Vol.64 (3)

2020

Volltextzugriff (PDF)

THE EUROPEAN MEDICINES AGENCY APPROVED THE NEW ANTIBACTERIAL DRUGS – RESPONSE TO THE 2017 WHO REPORT ON THE GLOBAL PROBLEM OF MULTI-DRUG RESISTANCE

Postępy mikrobiologii, 2021-12, Vol.60 (4)

2021

Volltextzugriff (PDF)

Mechanism of eravacycline resistance in Acinetobacter baumannii mediated by a deletion mutation in the sensor kinase adeS, leading to elevated expression of the efflux pump AdeABC

Infection, genetics and evolution, 2020-06, Vol.80, p.104185-104185, Article 104185

2020

Volltextzugriff (PDF)

In Vitro Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Antimicrobial agents and chemotherapy, 2020-07, Vol.64 (8)

2020

Volltextzugriff (PDF)

Cryo-EM Determination of Eravacycline-Bound Structures of the Ribosome and the Multidrug Efflux Pump AdeJ of Acinetobacter baumannii

mBio, 2021-06, Vol.12 (3)

2021

Volltextzugriff (PDF)

AdeABC Efflux Pump Controlled by AdeRS Two Component System Conferring Resistance to Tigecycline, Omadacycline and Eravacycline in Clinical Carbapenem Resistant Acinetobacter nosocomialis

Frontiers in microbiology, 2020-11, Vol.11, p.584789-584789

2020

Volltextzugriff (PDF)

Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials

International journal of antimicrobial agents, 2023-08, Vol.62 (2), p.106844-106844, Article 106844

2023

Volltextzugriff (PDF)

In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China

Diagnostic microbiology and infectious disease, 2020-11, Vol.98 (3), p.115129-115129, Article 115129

2020

Volltextzugriff (PDF)

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates

Frontiers in microbiology, 2022-11, Vol.13, p.1043736-1043736

2022

Volltextzugriff (PDF)

Comparative in vitro activities of omadacycline, eravacycline and tigecycline against non-ESBL-producing, ESBL-producing and carbapenem-resistant isolates of K. pneumoniae

Journal of medical microbiology, 2022-01, Vol.71 (10)

2022

Volltextzugriff (PDF)

Evaluation of the in vitro susceptibility of clinical isolates of NDM-producing Klebsiella pneumoniae to new antibiotics included in a treatment regimen for infections

Frontiers in microbiology, 2024, Vol.15, p.1331628-1331628

2024

Volltextzugriff (PDF)

1 – 25 von 177

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(128)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Eravacycline
(175)
Science & Technology
(133)
Life Sciences & Biomedicine
(132)
Microbiology
(71)
Pharmacology & Pharmacy
(70)
Infectious Diseases
(55)
Humans
(52)
Anti-Bacterial Agents - Pharmacology
(44)
Tetracyclines
(40)
Tigecycline
(40)
Microbial Sensitivity Tests
(39)
Omadacycline
(30)
Tetracyclines - Pharmacology
(30)
Antibiotics
(29)
Anti-Bacterial Agents - Therapeutic Use
(26)
Acinetobacter Baumannii
(20)
Drug Resistance
(20)
Infection
(19)
Drug Resistance, Multiple, Bacterial
(17)
Cefiderocol
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1/CCL5 mediated M1 macrophage polarization in melanoma

In vitro activities of the essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin, and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: a multicenter study in China, 2021

Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective

Comparison of antimicrobial activities and resistance mechanisms of eravacycline and tigecycline against clinical Acinetobacter baumannii isolates in China

Efficacy and safety of eravacycline: A meta-analysis

An in silico study on reproposing eravacycline as an MMP inhibitor

Achromobacter Infections and Treatment Options

Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance

2018 FDA drug approvals

In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015

Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline

IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections

Eravacycline -Synergistic activity with other antimicrobials in carbapenem resistant isolates of Escherichia coli and Acinetobacter baumannii

In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017

THE EUROPEAN MEDICINES AGENCY APPROVED THE NEW ANTIBACTERIAL DRUGS – RESPONSE TO THE 2017 WHO REPORT ON THE GLOBAL PROBLEM OF MULTI-DRUG RESISTANCE

Mechanism of eravacycline resistance in Acinetobacter baumannii mediated by a deletion mutation in the sensor kinase adeS, leading to elevated expression of the efflux pump AdeABC

In Vitro Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Cryo-EM Determination of Eravacycline-Bound Structures of the Ribosome and the Multidrug Efflux Pump AdeJ of Acinetobacter baumannii

AdeABC Efflux Pump Controlled by AdeRS Two Component System Conferring Resistance to Tigecycline, Omadacycline and Eravacycline in Clinical Carbapenem Resistant Acinetobacter nosocomialis

Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials

In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates

Comparative in vitro activities of omadacycline, eravacycline and tigecycline against non-ESBL-producing, ESBL-producing and carbapenem-resistant isolates of K. pneumoniae

Evaluation of the in vitro susceptibility of clinical isolates of NDM-producing Klebsiella pneumoniae to new antibiotics included in a treatment regimen for infections

Suchergebnisse filtern